The Use of Paclitaxel-Coated Devices in the Treatment of Peripheral Arterial Disease is Not Associated With Increased Mortality or Amputations

• Published in: Annals of vascular surgery Vol. 87; pp. 64 - 70
• Main Authors: Bair, Evan C., McCarver, Beau C., Cooper, Neal T., Greif, Benjamin A., Major, Matthew, Wang, Shengxuan, Lewis, Anthony J., Ryer, Evan J., Elmore, James R., Salzler, Gregory G.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2022
• ISSN: 0890-5096; 1615-5947
• DOI: 10.1016/j.avsg.2022.04.047

Strategies for the most effective treatment for peripheral arterial disease (PAD) remain controversial among clinicians. Several trials have shown improved primary patency of femoropopliteal interventions with the utilization of paclitaxel-coated balloons or stents compared to conventional balloons or stents. However, a 2018 meta-analysis suggested an increased mortality risk for patients receiving drug-coated balloons or stents (DCBS), resulting in an international pause in the use of DCBS. A 2021 meta-analysis by the same group suggested an increased risk of major amputation following DCBS use in peripheral arterial revascularization procedures. Here we report our long-term institutional outcomes comparing uncoated devices to DCBS. A retrospective review of all patients who underwent peripheral arterial angioplasty, stenting, atherectomy, or a combination between 2011 and 2020 within a regional healthcare system was performed. Univariate, multivariate, and survival analyses were performed using standard statistical methods to assess the primary end points of overall survival, 5-year survival, and amputation-free survival. A total of 2,717 patients were identified, of whom 1,965 were treated with conventional uncoated devices and 752 were treated with DCBS. A univariate analysis showed that patients treated with non-DCBS had higher rates of overall mortality, major amputations, and mortality at 1, 3, and 5 years. A multivariable analysis demonstrated that the use of conventional devices, age, diabetes, chronic kidney disease, myocardial infarction, transient ischemic attack, warfarin use, and atrial fibrillation all significantly increased the risk of 5-year mortality, overall mortality, and combined mortality and/or amputation. DCBS are not associated with increased mortality or worse amputation-free survival in this real-world cohort of patients treated for PAD. Our data suggest that mortality is more closely linked with pre-existing patient comorbidities rather than device selection at the time of revascularization. •Drug-coated balloons/stents were not associated with increased mortality or worse amputation-free survival in a large, real-world cohort of patients with peripheral arterial disease.•Mortality seems to be more closely linked with pre-existing patient comorbidities rather than device selection.